Age-related macular degeneration (ARMD) continues to be a significant public health concern, given its high prevalence and potential blinding prognosis in the elderly. Several risk factors have been identified in the development of ARMD, including age, race and family history. The pathogenesis of ARMD continues to be elucidated and recent research has focused on genetic factors. ARMD presents in either the atrophic or exudative form. Treatment for atrophic disease consists of antioxidants and zinc and close monitoring. Treatment for exudative disease is aimed at targeting choroidal neovascularisation. The development of anti-vascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of exudative ARMD, providing a more favourable prognosis for previously blinding disease. A considerable amount of research is being carried out on new treatment modalities for both the atrophic and exudative forms of the disease.
Age-related macular degeneration (ARMD) is a highly prevalent, severely visually disabling disease affecting millions of people worldwide. As its name implies, the disorder affects the macula and therefore central vision, causing significant disability and immeasurable personal impact not only to the patient, but also the family and loved ones caring for those afflicted. 
Epidemiology
ARMD is the major cause of severe central visual loss in the US in people over 60 years of age. 
Impact on Society
ARMD proves to be a major public health concern, not only because of its current and predicted increased prevalence, but also because of the disabling impact it has on those suffering vision loss as a result of advanced ARMD. ARMD has a dramatic impact on the elderly in terms of daily living and overall quality of life. 6, 7 Not only are visual impairments associated with difficulty with activities of daily living, but also with increased risk of depression and accidental injury. 8, 9 In addition, significant occupational impairment may result from even mild visual impairment. Furthermore, elderly patients with blinding disease have a higher likelihood of multiple sensory impairments.
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Risk Factors
Risk factors for the development of ARMD include advancing age, light skin pigmentation, hyperopia, family history, smoking, female gender, hypertension, hypercholesterolaemia and cardiovascular disease.
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Pathogenesis and Clinical Manifestations
The pathogenic basis of ARMD is diverse and complex, depending on the stage of disease. [20] [21] [22] A massive body of research has been undertaken in order to elucidate the genetic and environmental interplay that leads to the development of various stages and phenotypic variations of the disease. The atrophic form of the disease is characterised by macular RPE alterations, the accumulation of lipofuscin and drusen, retinal pigment epithelial atrophy and degeneration of segments of the choriocapillaris. 23, 24 Perhaps the earliest sign of the development of ARMD is the presence of macular drusen, or lipid-rich material with various amounts of collagen fibrils that accumulate at the level of the sub-RPE and Bruch's membrane 25 (see Figure 1 ).
Pigment changes early in the disease consist of more focal areas of RPE hyperpigmentation and areas of non-contiguous, mottled depigmentation. Histologically, this represents atrophic areas of RPE overlying drusen deposits. 26 As atrophic macular degeneration progresses, extensive areas of RPE and retinal atrophy ensue, leading to the late stage known as geographic atrophy. This stage is characterised ultrastructurally by RPE loss and damaged photoreceptors in association with abnormal distribution of opsins in degenerating cells, 27 with overlying thinning of the neurosensory retina. 28 Segments of the choriocapillaris underlying the degenerating RPE also become atrophic.
Drusen are classified by size, with small drusen considered to be <64µm, intermediate drusen 64-124µm and large drusen >125µm. 24 Larger drusen may give rise to areas of RPE detachment, sometimes referred to as a drusenoid pigment epithelial detachment (PED).
Larger-sized drusen, larger number of drusen, confluence of drusen and presence of soft drusen have been noted to be associated with more advanced atrophic as well as exudative forms of ARMD. haemorrhage at any layer (pre-, intra-, or subretinal or sub-RPE); RPE detachment; and/or presence of lipid (see Figure 2) . The end result of untreated neovascularisation is fibrotic scar formation, known as a disciform scar, with permanent central vision loss (see Figure 3 ).
Fluorescein angiography, indocyanine green angiography and optical coherence tomography (OCT) imaging are used to aid in the diagnosis of exudative ARMD.
The specific cascade of events that leads to this wet form of ARMD is complex and remains to be completely elucidated. 30 It is thought that focal defects in Bruch's membrane and oxidative stress may contribute to the pathophysiological development of choroidal neovascularisation. The polymorphism is significantly associated with both neovascular ARMD and geographic atrophy, as well as conferring a higher risk of bilateral disease. More recently, an additional locus on chromosome 10q LOC387715 that confers an independent risk of ARMD has been identified. 42 The apparent importance of genes involved in the complement cascade has led to further studies and identification of several additional candidate genes, including complement component 2. 43 Although several biological predispositions are known to exist and continue to be uncovered, the risk and development of ARMD has a highly complex and multifactorial aetiology. sham injections. 50 In the ANCHOR trial, 96% of subjects at 12 months and 90% at 24 months receiving monthly ranibizumab injections lost fewer than three lines of vision compared with 64 and 66%, respectively, receiving PDT. Furthermore, 40% at 12 months and 41% at 24 months gained three or more lines of vision compared with 6% at both 12 and 24 months receiving PDT. 51, 52 Bevacizumab is FDA approved for use in metastatic colorectal, lung and breast cancer and is being used off-label for the treatment of ARMD.
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